Relmada Therapeutics, Inc. (RLMD)
| Market Cap | 759.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.39M |
| Shares Out | 104.89M |
| EPS (ttm) | -1.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,097,103 |
| Open | 7.00 |
| Previous Close | 7.03 |
| Day's Range | 6.82 - 7.26 |
| 52-Week Range | 0.27 - 7.94 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 12.40 (+71.27%) |
| Earnings Date | May 8, 2026 |
About RLMD
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price target is $12.4, which is an increase of 71.27% from the latest price.
News
Relmada Therapeutics Earnings Call Transcript: Q4 2025
2025 saw major clinical and financial milestones, including strong NDV-01 phase II data, FDA alignment for phase III, and a $160M financing extending runway through 2029. NDV-01's efficacy and safety profile position it as a potential best-in-class NMIBC therapy.
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026
NDV-01, a sustained-release intravesical gel for bladder cancer, demonstrated high 12-month CR rates and a favorable safety profile, aiming to expand access beyond academic centers. Two pivotal studies will launch mid-year, with initial data expected by year-end. $160 million was raised in an oversubscribed financing.
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerabi...
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in...
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustai...
Relmada Therapeutics Earnings Call Transcript: Q3 2025
Strong nine-month phase II data for NDV-01 in NMIBC and FDA alignment on phase III program de-risk the pipeline. Financial position strengthened by a $100 million capital raise, supporting operations and clinical trials into 2028.
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, ...
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01
Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program
Relmada Therapeutics Transcript: Small-Cap Virtual Conference
A new extended-release chemotherapy gel for bladder cancer shows 90% cancer-free rates at six months, aiming to offer a more convenient and cost-effective alternative to current high-priced treatments. Financials remain solid, with additional funding anticipated to support clinical milestones.
Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
CORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Issues Mid-Year CEO Letter to Shareholders
CORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...
Relmada Therapeutics Earnings Call Transcript: Q2 2025
Six-month phase II data for NDB01 in high-risk NMIBC showed a 91% response rate and strong safety, while Sepranolone advances toward a phase II study in Prader-Willi syndrome. Cash balance stands at $20.6 million, with reduced R&D spend ahead of new trial initiations.
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with u...
Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for o...
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01
Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 C...
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors
Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative Appointment highlights DIMERx's next phase of growth as it...
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., J...
Relmada Therapeutics Earnings Call Transcript: Q1 2025
Two new product candidates with positive phase II data were added, including NDV-01 for bladder cancer, which showed high response rates and strong safety, and sepranolone for neurobehavioral disorders. Cash balance was $27.1 million, with reduced expenses and a focus on advancing both programs to key milestones.